Abstract:Modern drug design aims to discover novel lead compounds with attractable chemical profiles to enable further exploration of the intersection of chemical space and biological space. Identification of small molecules with good ligand efficiency, high activity, and selectivity is crucial toward developing effective and safe drugs. However, the intersection is one of the most challenging tasks in the pharmaceutical industry, as chemical space is almost infinity and continuous, whereas the biological space is very limited and discrete. This bottleneck potentially limits the discovery of molecules with desirable properties for lead optimization. Herein, we present a new direction leveraging posttranslational modification (PTM) protein isoforms target space to inspire drug design termed as "Post-translational Modification Inspired Drug Design (PTMI-DD)." PTMI-DD aims to extend the intersections of chemical space and biological space. We further rationalized and highlighted the importance of PTM protein isoforms and their roles in various diseases and biological functions. We then laid out a few directions to elaborate the PTMI-DD in drug design including discovering covalent binding inhibitors mimicking PTMs, targeting PTM protein isoforms with distinctive binding sites from that of wild-type counterpart, targeting protein-protein interactions involving PTMs, and hijacking protein degeneration by ubiquitination for PTM protein isoforms. These directions will lead to a significant expansion of the biological space and/or increase the tractability of compounds, primarily due to precisely targeting PTM protein isoforms or complexes which are highly relevant to biological functions. Importantly, this new avenue will further enrich the personalized treatment opportunity through precision medicine targeting PTM isoforms.

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Targeting Protein-Protein Interaction by Small Molecules

Small molecules targeting protein‒protein interactions for cancer therapy

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Hotspot Identification and Drug Design of Protein-Protein Interaction Modulators Using the Fragment Molecular Orbital Method

Chemical-Protein Interactome and Its Application in Off-Target Identification

Revisiting Pyrimidine-Embedded Molecular Frameworks to Probe the Unexplored Chemical Space for Protein-Protein Interactions

Peptide therapeutics: Targeting the undruggable space

Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives

Main methods and tools for peptide development based on protein-protein interactions (PPIs)

Benchmark Study Based on 2P2I(DB) to Gain Insights into the Discovery of Small-Molecule PPI Inhibitors

Exploring the chemical space of protein–protein interaction inhibitors through machine learning

Deciphering the Lexicon of Protein Targets: A Review on Multifaceted Drug Discovery in the Era of Artificial Intelligence

Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering

What Makes a Good Protein–Protein Interaction Stabilizer: Analysis and Application of the Dual-Binding Mechanism

Polymers for Disrupting Protein-Protein Interactions: Where Are We and Where Should We Be?

A Comprehensive Review on Current Advances in Peptide Drug Development and Design

Drug design targeting active posttranslational modification protein isoforms

Modulators of 14-3-3 Protein–Protein Interactions